Eye drops that are typically used to treat irritation and dryness of eyes are called artificial tears. Comprised of polymers and water and salts, artifial tears, as the name suggests, are made to resemble real eye tears and address a number of eye problems. However, as opposed to real eye tears, artificial tears do not contain any proteins. One of the main diseases being addressed by artificial tears is dry eye syndrome (DES). This is also one of the key factors driving the growth of this market. DES is condition being reported not only amongst senior citizens, but even across the young generation of individuals. The reason for this is the kind of lifestyle being led by the young working class that involves poor dietary intake and long hours in front of a computer, phone or tablet. Apart from this, frequent air travel and rising pollution levels are other factors attributing to the rise of DES. Also, the probablity of being affected with DES increases with age and contact lens users are also more susceptible to this condition. Artificial tears are usually the first line of medication prescribed by any physician for symptoms related to DES.
While artificial tears are easily available over the counter remedies for DES, the use of artificial tears also has side effects that need to be kept in mind. Also, with some patients who require the use of artificial tears several times a day, regular artificial tears are not a good option. Technological advances associated with several years of research and development has addressed this issue with preservative free artificial tears.
The Artificial Tears market can be segmented on the basis of type as
- Cellulose-derived tears
- Glycerin-derived tears
- polyethylene glycol and propylene glycol based tears
- Oil-based emulsion tears
In terms of end-user age group, the Artificial Tears market has been segmented across the following:
- 20-40 years
- 40-60 years
- Above 60 years of age
While the growth potential in regions such as Europe and North America still exist, the opportunities in developing economies in South America and APAC are poised to grow at higher rates comparatively. In Europe, an increasing ageing population is one aspect that will enhance the growth of the market. Changing lifestyles resulting in an increasing number of DES patients coupled with the increasing spending power of the population in these regions is expected to drive the growth of the artificial tear market in South America and Asia Pacific.
The market has been segmented based on the following geographies:
- North America
- South America
- Middle East
Following are just a few of the companies that are operating in the Artificial Tears market:
- Abott Medical Optics Inc
- Akorn Inc
- Johnson & Johnson
- Bausch and Lomb
1. Artificial Tears– Market Overview
2. Executive Summary
3. Artificial Tears– Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Artificial Tears– Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Artificial Tears Market
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Artificial Tears Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Artificial Tears Market– By Type:
6.1. Cellulose-derived tears
6.2. Glycerin-derived tears
6.3. Polyethylene glycol and propylene glycol based tears
6.4. Oil-based emulsion tears
7. Artificial Tears Market– By End-user Age Group:
7.1. 20-40 years
7.2. 40-60 years
7.3. Above 60 years
8. Artificial Tears Market– By Geography:
8.2. Global Study
8.3.1. North America
9. Artificial Tears Market– Market Entropy
9.1. New Product Launches
9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles
10.1. Bausch and Lomb
10.2. Abott Medical Optics, Inc.
10.3. Johnson and Johnson
10.4. Novartis International AG
10.5. Allergan, Inc.
10.6. Akorn, Inc.
10.7. Santen Pharmaceuticals
10.8. Novagali Pharma S.A.
10.10. Alcon, Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11.3. Research Methodology
11.5. Compilation of Expert Insights